Metastatic Breast Cancer in Austria

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorArbeitsgemeinschaft medikamentoese Tumortherapie

About this trial

Breast cancer is the most common cancer among women worldwide. In Austria, this diagnosis is made more than 5000 times a year (STATISTICS AUSTRIA, Austrian Cancer Registry, as of 24.09.2012). Of these, already 5% to 10% have distant metastases at the time of initial diagnosis, and up to 30% of the node-negative tumours and up to 70% of the node-positive tumours metastasise at a later date. Metastatic breast cancer has not been systematically assessed in Austria to date. This medical registry of the AGMT is thus the first Austrian-wide standardised documentation of this disease. The aim of the registry is to answer both epidemiological and therapy-specific questions.

This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria. All tumour characteristics, medical histories and also treatment sequences are documented in anonymised form.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Histological evidence of breast cancer

Histological and/or radiological evidence of metastases

Metastasis within 10 years of registry initiation

Signed informed consent (if a patient has already died at the time of entry, the entry can be made without a declaration of consent)

Disqualifiers

Due to the non-interventional design of the registry there are no specific exclusion criteria.

Trial population

This registry is a prospective and retrospective, multicentre collection of data on patients with metastatic breast cancer in Austria.

Trial design

Design model

Other

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Number of patients with prognostic factors for metastatic breast cancer

Time frame
10 years
2

Number of patients according to molecular subtypes

Time frame
10 years
3

Frequency and tumour characteristics of breast cancer in male patients

Time frame
10 years
4

Overall survival of patients with metastatic breast cancer in Austria

Time frame
10 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Arbeitsgemeinschaft medikamentoese Tumortherapie

Lead sponsor

Hoffmann-La Roche

Collaborator

Daiichi Sankyo

Collaborator

Pfizer

Collaborator

Novartis

Collaborator

Caris Life Sciences

Collaborator

AstraZeneca

Collaborator

Seagen Inc.

Collaborator

Eli Lilly and Company

Collaborator